Arjo Valuation
Is ARJO B undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
6/6Valuation Score 6/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of ARJO B when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: ARJO B (SEK38.96) is trading below our estimate of fair value (SEK117.25)
Significantly Below Fair Value: ARJO B is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ARJO B?
Other financial metrics that can be useful for relative valuation.
| What is ARJO B's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | SEK 10.61b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.4x |
| Enterprise Value/EBITDA | 10.6x |
| PEG Ratio | 1.1x |
Price to Earnings Ratio vs Peers
How does ARJO B's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 48.1x | ||
CEVI CellaVision | 40.2x | 24.1% | SEK 5.8b |
EKTA B Elekta | 18.4x | 14.4% | SEK 23.9b |
ELOS B Elos Medtech | 104.3x | n/a | SEK 5.7b |
SUS Surgical Science Sweden | 29.4x | 27.0% | SEK 6.1b |
ARJO B Arjo | 20.7x | 18.6% | SEK 10.6b |
Price-To-Earnings vs Peers: ARJO B is good value based on its Price-To-Earnings Ratio (20.7x) compared to the peer average (48.1x).
Price to Earnings Ratio vs Industry
How does ARJO B's PE Ratio compare vs other companies in the European Medical Equipment Industry?
Price-To-Earnings vs Industry: ARJO B is good value based on its Price-To-Earnings Ratio (20.7x) compared to the European Medical Equipment industry average (29.1x).
Price to Earnings Ratio vs Fair Ratio
What is ARJO B's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 20.7x |
| Fair PE Ratio | 23.3x |
Price-To-Earnings vs Fair Ratio: ARJO B is good value based on its Price-To-Earnings Ratio (20.7x) compared to the estimated Fair Price-To-Earnings Ratio (23.3x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | SEK 38.96 | SEK 51.80 +33.0% | 11.3% | SEK 58.00 | SEK 42.00 | n/a | 5 |
| Jul ’25 | SEK 40.84 | SEK 51.25 +25.5% | 18.4% | SEK 58.00 | SEK 35.00 | n/a | 4 |
| Jun ’25 | SEK 46.32 | SEK 51.25 +10.6% | 18.4% | SEK 58.00 | SEK 35.00 | n/a | 4 |
| May ’25 | SEK 46.72 | SEK 51.25 +9.7% | 18.4% | SEK 58.00 | SEK 35.00 | n/a | 4 |
| Apr ’25 | SEK 51.15 | SEK 51.60 +0.9% | 17.1% | SEK 60.00 | SEK 35.00 | n/a | 5 |
| Mar ’25 | SEK 48.82 | SEK 51.60 +5.7% | 17.1% | SEK 60.00 | SEK 35.00 | n/a | 5 |
| Feb ’25 | SEK 48.94 | SEK 50.60 +3.4% | 16.6% | SEK 60.00 | SEK 35.00 | n/a | 5 |
| Jan ’25 | SEK 39.40 | SEK 44.25 +12.3% | 22.5% | SEK 55.00 | SEK 30.00 | n/a | 4 |
| Dec ’24 | SEK 38.68 | SEK 44.25 +14.4% | 22.5% | SEK 55.00 | SEK 30.00 | n/a | 4 |
| Nov ’24 | SEK 37.12 | SEK 50.00 +34.7% | 14.1% | SEK 55.00 | SEK 40.00 | n/a | 3 |
| Oct ’24 | SEK 42.32 | SEK 50.67 +19.7% | 12.1% | SEK 55.00 | SEK 42.00 | n/a | 3 |
| Sep ’24 | SEK 42.72 | SEK 50.33 +17.8% | 13.1% | SEK 55.00 | SEK 41.00 | n/a | 3 |
| Aug ’24 | SEK 43.78 | SEK 50.33 +15.0% | 13.1% | SEK 55.00 | SEK 41.00 | SEK 40.80 | 3 |
| Jul ’24 | SEK 39.08 | SEK 50.67 +29.6% | 12.1% | SEK 55.00 | SEK 42.00 | SEK 40.84 | 3 |
| Jun ’24 | SEK 41.28 | SEK 52.33 +26.8% | 14.5% | SEK 60.00 | SEK 42.00 | SEK 46.32 | 3 |
| May ’24 | SEK 45.36 | SEK 46.67 +2.9% | 20.5% | SEK 60.00 | SEK 38.00 | SEK 46.72 | 3 |
| Apr ’24 | SEK 40.46 | SEK 44.33 +9.6% | 25.1% | SEK 60.00 | SEK 35.00 | SEK 51.15 | 3 |
| Mar ’24 | SEK 38.52 | SEK 44.33 +15.1% | 25.1% | SEK 60.00 | SEK 35.00 | SEK 48.82 | 3 |
| Feb ’24 | SEK 39.96 | SEK 46.67 +16.8% | 22.0% | SEK 60.00 | SEK 35.00 | SEK 48.94 | 3 |
| Jan ’24 | SEK 38.94 | SEK 53.25 +36.7% | 15.6% | SEK 63.00 | SEK 45.00 | SEK 39.40 | 4 |
| Dec ’23 | SEK 42.38 | SEK 60.75 +43.3% | 6.2% | SEK 65.00 | SEK 55.00 | SEK 38.68 | 4 |
| Nov ’23 | SEK 44.22 | SEK 63.25 +43.0% | 11.6% | SEK 75.00 | SEK 55.00 | SEK 37.12 | 4 |
| Oct ’23 | SEK 40.94 | SEK 74.50 +82.0% | 13.3% | SEK 90.00 | SEK 63.00 | SEK 42.32 | 4 |
| Sep ’23 | SEK 46.72 | SEK 79.50 +70.2% | 10.4% | SEK 90.00 | SEK 70.00 | SEK 42.72 | 4 |
| Aug ’23 | SEK 55.10 | SEK 79.50 +44.3% | 10.4% | SEK 90.00 | SEK 70.00 | SEK 43.78 | 4 |
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.